Stockscreener 앱 받기
18.00
2.60%
-0.48
시간 외 거래:
18.12
0.12
+0.67%
Viatris Inc 주식(VTRS)의 최신 뉴스
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.
What US Small Cap Value Portfolio ETF (DFSV) Bought: Dick's Leads on Wednesday - Yahoo Finance
Form 4 Viatris Inc: David S. Simmons (Director) For: 30 September - Investing.com UK
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada
Pacira BioSciences jumps 44% after Viatris agre... - Pluang
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
A $36.50-a-share cash deal would add a wholly owned subsidiary to Viatris (VTRS). - Stock Titan
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com South Africa
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc. - Ashurst Perkins Coie
Doubling up in pain: Viatris pays $1.65B, Pacira gets relief - BioWorld News
VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research
Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research
Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
More than 300,000 people took part in Forbes' employer survey; Viatris made the list. - Stock Titan
Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street
Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView
Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
0.46%
0.41%
자본화:
|
볼륨(24시간):